Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia Full Text
Clinical Cancer Research, 05/16/2012
Vitale L et al. – The data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX–1127, may provide direct anti–tumor activity against CD27 expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties.



